Key result
17β-estradiol attenuates phenylephrine- and endothelin-1-induced cardiomyocyte hypertrophy by inducing atrial natriuretic factor expression and stimulating a cGMP-dependent protein kinase pathway.
17β-estradiol antagonizes cardiomyocyte hypertrophy through an autocrine/paracrine mechanism involving ANF induction and a cGMP-dependent protein kinase pathway.
No takes yet. Share an insight, caveat, or question.
Does not change clinical practice; leaves open estrogen signaling as a hypertrophy target for future human studies.
Babiker et al. (2004) studied Left ventricular hypertrophy. 17β-estradiol (E2) vs. Phenylephrine or endothelin-1 alone was evaluated on Cardiomyocyte hypertrophy and atrial natriuretic factor (ANF) expression. 17β-estradiol attenuates phenylephrine- and endothelin-1-induced cardiomyocyte hypertrophy by inducing atrial natriuretic factor expression and stimulating a cGMP-dependent protein kinase pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: